Literature DB >> 1721487

Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer.

M Nagamani1, C A Stuart, P A Dunhardt, M G Doherty.   

Abstract

Insulin and insulin-like growth factor I are known to be mitogenic and therefore may play a role in the development of endometrial cancer. We undertook this study to investigate whether human endometrial cancer tissue has receptors for these substances. Endometrial cancer tissue samples were obtained at hysterectomy from 10 women with endometrial cancer, and control endometrial tissue was collected from normal cycling women undergoing hysterectomy for nonendocrine problems. Binding studies with iodine 125-insulin and [125I]insulin-like growth factor I revealed the presence of specific binding sites for insulin and insulin-like growth factor I in both normal endometrium and endometrial cancer tissue. The percent binding of [125I]insulin in the endometrial cancer tissue (mean +/- SE 2.4% +/- 0.5%/100 micrograms protein) was not significantly different from that in normal endometrium (3.5% +/- 1%/100 micrograms protein). On the contrary, the percent total binding of [125]insulin-like growth factor I in the endometrial cancer (5.3% +/- 1.5%/100 micrograms protein) was significantly (p less than 0.04) higher than that observed in normal endometrium (2.1% +/- 0.4%/100 micrograms protein). There was a significant positive correlation between the histologic grade of the tumor and the insulin-like growth factor I binding (r = 0.865, p less than 0.02). The affinity constants for the high-affinity receptors were similar in the normal and neoplastic endometrium. These results indicate that insulin and insulin-like growth factor I may play a role in the growth and development of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721487     DOI: 10.1016/0002-9378(91)90047-u

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Role of metformin in the management of polycystic ovary syndrome.

Authors:  Hany Lashen
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

2.  Prospective evaluation of insulin resistance among endometrial cancer patients.

Authors:  Jennifer K Burzawa; Kathleen M Schmeler; Pamela T Soliman; Larissa A Meyer; Michael W Bevers; Terri L Pustilnik; Matthew L Anderson; Lois M Ramondetta; Guillermo Tortolero-Luna; Diana L Urbauer; Shine Chang; David M Gershenson; Jubilee Brown; Karen H Lu
Journal:  Am J Obstet Gynecol       Date:  2011-02-16       Impact factor: 8.661

3.  Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells.

Authors:  M A Steller; C H Delgado; Z Zou
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

4.  Insulin stimulates transepithelial sodium transport by activation of a protein phosphatase that increases Na-K ATPase activity in endometrial epithelial cells.

Authors:  C Deachapunya; M Palmer-Densmore; S M O'Grady
Journal:  J Gen Physiol       Date:  1999-10       Impact factor: 4.086

5.  Association of IGF-1 CA(n) and IGFBP3 rs2854746 Polymorphisms with Endometrial Polyp Risk.

Authors:  Pedro Leopoldo Silva Doria; Thomas Moscovitz; Marcos Tcherniakovsky; Cesar Eduardo Fernandes; Luciano Melo Pompei; Milton Wajman; Angela Van Nimwegen; Sergio Haimovich
Journal:  Biomed Res Int       Date:  2018-12-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.